title: A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
abstract: BACKGROUND
  Peripheral T-cell lymphomas are aggressive lymphomas that have no standard treatment. Studies suggest that HD-ASCT in the first CR improves outcome. Few data exist regarding allo-HSCT in the first CR.
  
  
  METHODS
  We retrospectively identified patients (2001-2011) with PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, initially treated with CHOP, CHOP-ICE (ifosfamide, carboplatin, etoposide), or other therapy with the intention to transplant in the first CR. Disease characteristics, therapy, progression-free survival (PFS), and OS were evaluated.
  
  
  RESULTS
  Sixty-five patients were identified. PFS and OS were 38% and 52%, respectively, at 4 years. CHOP and CHOP-ICE regimens had similar outcomes. Treatment with allo-HSCT and HD-ASCT had OS at 4 years of 66% and 67%, respectively. Patients who did not proceed to transplant had OS of 27%. IPI score ≤ 2 and Prognostic Index for T-cell Lymphomas scores ≤ 1 predicted improved outcome. Combined analysis of interim response to CHOP and IPI score also predicted PFS and OS.
  
  
  CONCLUSIONS
  Our results support consolidation of first CR with transplantation. The addition of etoposide did not improve outcomes. Baseline IPI and interim response to CHOP can predict outcomes and guide decisions about transplantation in first CR in PTCL. Randomized trials are necessary to confirm the efficacy of this approach.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: mehtan1@mskcc.org.
authors.forename: Neha
authors.initials: N
authors.lastname: Mehta
authors.forename: Jocelyn C
authors.initials: JC
authors.lastname: Maragulia
authors.forename: Allison
authors.initials: A
authors.lastname: Moskowitz
authors.forename: Paul A
authors.initials: PA
authors.lastname: Hamlin
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Lunning
authors.forename: Craig H
authors.initials: CH
authors.lastname: Moskowitz
authors.forename: Andrew
authors.initials: A
authors.lastname: Zelenetz
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Matasar
authors.forename: Craig
authors.initials: C
authors.lastname: Sauter
authors.forename: Jenna
authors.initials: J
authors.lastname: Goldberg
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
keywords: Allogeneic; Autologous; Non-hodgkin's lymphoma; PTCL; Transplantation